PTC Therapeutics (NASDAQ: PTCT) revenue
PTC Therapeutics reported revenue of $1,731m for fiscal 2025, 114.5% more than in fiscal 2024 ($806.8m). Since fiscal 2016 its revenue has grown by 1,992.6%, an average growth of 40.2% a year.
Fiscal 2025 is the highest of the 10 fiscal years on record for PTC Therapeutics. The biggest drop was in fiscal 2024, −14.0%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $1,731m | +114.5% | $866.9m | 50.1% |
| 2024 | $806.8m | −14.0% | −$302.6m | −37.5% |
| 2023 | $937.8m | +34.2% | −$439.5m | −46.9% |
| 2022 | $698.8m | +29.7% | −$447.4m | −64.0% |
| 2021 | $538.6m | +41.4% | −$374.4m | −69.5% |
| 2020 | $380.8m | +24.0% | −$431.8m | −113.4% |
| 2019 | $307.0m | +16.0% | −$241.2m | −78.6% |
| 2018 | $264.7m | +36.2% | −$115.7m | −43.7% |
| 2017 | $194.4m | +135.0% | −$64.3m | −33.1% |
| 2016 | $82.7m | — | −$132.1m | −159.7% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
PTC Therapeutics revenue compared with its sector
By revenue for its latest fiscal year, PTC Therapeutics ranks 121st of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; PTC Therapeutics, 114.5%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 119th | Integer | $1,854m | 8.0% |
| 120th | Healthcare Services Group | $1,837m | 7.1% |
| 121st | PTC Therapeutics | $1,731m | 114.5% |
| 122nd | Integra Lifesciences | $1,635m | 1.5% |
| 123rd | Lantheus | $1,542m | 0.5% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of PTC Therapeutics
- How much revenue did PTC Therapeutics make in fiscal 2025?
- PTC Therapeutics reported revenue of $1,731m for fiscal 2025, compared with $806.8m in fiscal 2024.
- How much has the revenue of PTC Therapeutics grown?
- Between fiscal 2016 and fiscal 2025 it went from $82.7m to $1,731m: 1,992.6% more, an average growth of 40.2% a year.
- What was the best year for revenue at PTC Therapeutics?
- Of its last 10 fiscal years, fiscal 2025, with $1,731m.
- Where does PTC Therapeutics rank in its sector by revenue?
- It ranks 121st of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for PTC Therapeutics come from?
- From the annual report (Form 10-K) that PTC Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that PTC Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on PTC Therapeutics: the PTC Therapeutics page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.